NCT07504198Not yet recruitingPhase 2/3
Neuroprotection of Memantine and Rosuvastatin
Neuroprotective Effect of Memantine and Rosuvastatin Against Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 31 Mar 2026
Brief summary (registry, in English)
Memantine is used to slow the neurotoxicity of Alzheimer disease. Rosuvastatin used as a lipid-lowering agent . Increased bioavailability of endothelial-derived nitric oxide improves endothelium function , increases cerebral blood flow which may all contribute to the neuroprotective effects of rosuvastatin . The goal of this clinical trial is to prevent oxaliplatin induced peripheral neuropathy in patients with colorectal cancer.The aim of this current study is to assess the neuroprotective effect of memantine and rosuvastatin against oxaliplatin induced peripheral neuropathy.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- First submitted
- 15 Mar 2026
- Start date
- Mar 2026
- Primary completion date
- Apr 2027
- Lead sponsor
- Tanta University
- Diseases
- Colorectal cancer
- NCT number
- NCT07504198
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 46
- From Mar 2026 to the primary completion date, Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior exposure to neurotoxic chemotherapy (oxaliplatin, cisplatin, vincristine, paclitaxel, or docetaxel, INH).
- Concomitant use of multivitamins (vitamins E, C, A), tricyclic antidepressants, other neuro-protective medications (gabapentin, lamotrigine, carbamazepine and phenytoin).
- Concurrent active cancer originating from a primary site other than colon or rectum.
Other illness
- Patients with diabetes and other conditions that predispose to neuropathy as hypothyroidism, autoimmune diseases, hepatitis C.
- History of known allergy to oxaliplatin or other platinum agents.
- Patients with other inflammatory or stressful conditions.
Lab values
- Patients on amantadine , acetazolamide, dextromethorphan, aluminum hydroxide magnesium hydroxide and febuxostat .
- Sever renal insufficiency (creatinine clearance \< 25 ml/ minute) .
Age
- Children \< 18 years old.
Other
- Pregnant and breastfeeding women.
Who the study is looking for
- Age above 18 years old for both gender .
- Adequate baseline hematologic values (absolute neutrophil count ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L and hemoglobin level ≥ 10 g/dl).
- Patients with adequate renal function (serum creatinine \< 1.5 mg/dl or creatinine clearance ˃ 45 mL/min).
- Patients with adequate liver function (serum bilirubin \< 1.5 mg/dl).
- Patients with performance status \<2 according to Eastern Cooperative Oncology Group (ECOG) score.
- Patients who will be scheduled to receive modified FOLFOX-6 or XELOX regimen.
- Patients with histologically confirmed diagnosis of stage III or stage IV colorectal cancer.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tanta Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.